PALATIN TECHNOLOGIES INCPTNEarnings & Financial Report
Palatin Technologies Inc. is a biopharmaceutical firm developing targeted receptor-specific therapeutic products for unmet medical needs across cardiovascular care, renal disease treatment, and sexual health segments. It serves patients and healthcare providers mainly in North American and global pharmaceutical markets.
PTN Q2 FY2026 Key Financial Metrics
Revenue
$116.0K
Gross Profit
N/A
Operating Profit
$-7.3M
Net Profit
$-7.3M
Gross Margin
N/A
Operating Margin
-6315.8%
Net Margin
-6260.0%
YoY Growth
104.4%
EPS
$-2.86
PALATIN TECHNOLOGIES INC Q2 FY2026 Financial Summary
PALATIN TECHNOLOGIES INC reported revenue of $116.0K (up 104.4% YoY) for Q2 FY2026, with a net profit of $-7.3M (down 197.4% YoY) (-6260.0% margin).
Key Financial Metrics
| Total Revenue | $116.0K |
|---|---|
| Net Profit | $-7.3M |
| Gross Margin | N/A |
| Operating Margin | -6315.8% |
| Report Period | Q2 FY2026 |
PALATIN TECHNOLOGIES INC Annual Revenue by Year
PALATIN TECHNOLOGIES INC annual revenue history includes year-by-year totals (for example, 2023 revenue was $4.9M).
PALATIN TECHNOLOGIES INC Quarterly Revenue & Net Profit History
PALATIN TECHNOLOGIES INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2026 | $116.0K | +104.4% | $-7.3M | -6260.0% |
| Q1 FY2026 | $8.8M | — | $4.7M | 52.9% |
| Q3 FY2025 | $0 | — | $-4.8M | N/A |
| Q1 FY2025 | $0 | — | $-7.8M | N/A |
| Q3 FY2024 | $0 | — | $-8.4M | N/A |
| Q2 FY2024 | $2.0M | +98.2% | $-7.8M | -385.6% |
| Q1 FY2024 | $2.1M | +142.2% | $-5.2M | -247.2% |
| Q4 FY2023 | $1.8M | +128.6% | $-9.8M | -557.3% |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q3 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.8M | $2.1M | $2.0M | $0 | $0 | $0 | $8.8M | $116036 |
| YoY Growth | 128.6% | 142.2% | 98.2% | N/A | N/A | N/A | N/A | 104.4% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q3 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $17.9M | $11.2M | $13.6M | $11.4M | $3.4M | $3.7M | $8.6M | $17.9M |
| Liabilities | $19.7M | $16.1M | $24.5M | $9.8M | $11.1M | $10.1M | $8.2M | $6.5M |
| Equity | $-2.0M | $-6.3M | $-11.4M | $1.6M | $-7.7M | $-6.4M | $396399 | $11.5M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q3 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-9.6M | $-5.9M | $-10.5M | $-8.6M | $-7.0M | $-5.4M | $-1.6M | $-4.8M |